Here are 10 key developments from Zimmer Biomet so far in 2025.
1. The company entered into a definitive agreement to purchase Paragon 28, a medical device company focused exclusively on foot-and-ankle orthopedics.
2. John Sperling, MD, of Rochester, Minn.-based Mayo Clinic performed the first cases with Zimmer Biomet’s OsseoFit stemless shoulder system.
3. Non-executive chair Chris Begley plans to retire from the board on May 29, and Michael Farrell will become lead independent director. Mr. Begley has been a member of the board since 2012 and took his first leadership role in 2021.
4. Zimmer Biomet appointed Kristen Cardillo to serve as senior vice president and chief communications officer.
5. Zimmer Biomet was named on the 2025 “World’s Most Ethical” list. The list recognizes 136 organizations “for their unwavering commitment to business integrity.” Ethisphere, which develops the list, uses its EthicsQuotient to evaluate companies.
6. Zimmer Biomet’s CEO, Ivan Tornos, earned $15 million in total compensation in 2024, according to a March 29 Securities and Exchange Commission proxy filing.
7. Zimmer Biomet completed its acquisition of Paragon 28, a medical device company in the foot-and-ankle orthopedic sector.
8. Zimmer Biomet’s revenue in the first quarter of 2025 was mostly flat with a 1.1% increase year-over-year, according to financial results posted May 5.
9. Zimmer Biomet named Kevin Thornal as group president for global business and the Americas.
10. Zimmer Biomet CEO Ivan Tornos said he anticipates ASCs to be a major support for growing orthopedic case volumes during the Barclays 27th Annual Global Healthcare Conference. Mr. Tornos said he expected to see 40% to 60% of all surgical cases going to the ASC within three to five years.
